Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

ProM The ProM platform: New ways to drug the undruggable

Coordinator
Prosion GmbH, Germany
Runs
1 April 2022 to 31 March 2025
Status
Running
EU funding
€2.5m
Total cost
€3.5m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190154511

What the project is doing

In the project's own words, from its summary on CORDIS.

Existing pharmaceutical methods can only target 15% of all proteins in the human proteome. Given this limitation, pharmaceutical companies are running out of options to develop effective drugs to tackle hard-to-treat diseases. To have a better chance of fighting these diseases, further targets of the remaining, so far undruggable 85% of our proteome need to be unlocked. PROSION developed a disruptive platform of chemical building blocks called ProMs.

The ProM-platform addresses a specific class of yet undruggable proteins linked to hard-to-treat-diseases. ProMs can be combined into small molecule drugs to target proteins that play a key-role in pathologies such as cancer, Alzheimer’s, cardiovascular diseases and immune mediated disorders. The platform’s potential is currently being validated: in its first project, PROSION addresses a yet undruggable target to potentially provide new therapies for pancreatic and breast cancer and fight drug-resistance effects within cancer therapies.

Topics

Who is involved

OrganisationCityCountryRole
Prosion GmbHKolnGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI